Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome
Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Josie Montegaard(Dana-Farber Cancer Institute), Sigrid Berg, Karen Francoeur(Dana-Farber Cancer Institute), Jessica Lowney(Dana-Farber Cancer Institute), Allan Louie Cruz, Jacob D. Soumerai(Harvard University), Zixu Wang(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Lisa Brennan(Harvard University), Austin I. Kim(Dana-Farber Cancer Institute), Alexandra Savell(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 14
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752